Nasdaq grts.
The 36-month beta value for GRTS is also noteworthy at 0.44. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”. The average price estimated by analysts for GRTS is $10.40, which is $9.08 above than the current price.
Gritstone bio, Inc. (NASDAQ:GRTS) shares rose 37% to $1.63 in pre-market trading after the company announced it was awarded a BARDA contract to conduct a Phase 2b comparative study evaluating a ...EMERYVILLE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Eric Enderson. November 21, 2023. In the last trading session, 1.28 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.47. With the company’s per share price at $1.32 changed hands at -$0.04 or -2.94% during last session, the market valuation stood at $125.85M. GRTS’s last price was a discount ...
The latest price target for . Gritstone Bio (NASDAQ: GRTS) was reported by Piper Sandler on Thursday, September 28, 2023.The analyst firm set a price target for 7.00 expecting GRTS to rise to ...
16 พ.ค. 2566 ... HC Wainwright & Co. Reiterates Gritstone Bio (GRTS) Buy Recommendation ... Fintel reports that on May 15, 2023, HC Wainwright & Co. reiterated ...
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.The latest price target for . Gritstone Bio (NASDAQ: GRTS) was reported by Piper Sandler on Thursday, September 28, 2023.The analyst firm set a price target for 7.00 expecting GRTS to rise to ...Oct 30, 2023 · In the last trading session, 1.12 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.61. With the company’s per share price at $1.89 changed hands at -$0.06 or -3.08% during last session, the market valuation stood at $175.92M. GRTS’s last price was a 16 พ.ค. 2566 ... HC Wainwright & Co. Reiterates Gritstone Bio (GRTS) Buy Recommendation ... Fintel reports that on May 15, 2023, HC Wainwright & Co. reiterated ...EMERYVILLE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...
Jan 9, 2022 · Insiders seem to have made the most of their holdings by selling US$221k worth of Gritstone bio, Inc. (NASDAQ:GRTS) stock at an average sell price of US$22.10 during the past year. The company's ...
A. Gritstone Bio ( GRTS) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $1.6M, which ...
You can practice and explore trading GRTS stock methods without spending real money on the virtual paper trading platform. Webull offers GRTS Ent Holdg (GRTS) historical stock prices, in-depth market analysis, NASDAQ: GRTS real-time stock quote data, in-depth charts, free GRTS options chain data, and a fully built financial calendar to help you ...Gritstone bio (GRTS) Stock Price, News & Analysis $1.37 -0.01 (-0.72%) (As of 11/14/2023 ET) Compare Today's Range $1.36 $1.49 50-Day Range $1.19 $2.85 52-Week Range $1.14 $4.05 Volume 1.57 million shs Average Volume 1.17 million shs Market Capitalization $130.62 million P/E Ratio N/A Dividend Yield N/A Price Target $7.33Gritstone bio, Inc. Common Stock (GRTS) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.WebEMERYVILLE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.
Vaccine-developer Gritstone bio ( NASDAQ: GRTS) trended higher on Tuesday after B. Riley launched its coverage with a Buy rating and a 12-month target of $8 per share, noting its prospects in ...EMERYVILLE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Shares of NASDAQ GRTS opened at $1.37 on Friday. The company has a market capitalization of $130.62 million, a price-to-earnings ratio of -1.10 and a beta of 0.62. The company has a debt-to-equity ...Gritstone Bio Inc (NASDAQ: GRTS)’s stock price has soared by 17.69 in relation to previous closing price of 1.30. Nevertheless, the company has seen a gain of 11.68% in its stock price over the last five trading days. Zacks Investment Research reported 2023-10-16 that Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy ...Oct 14, 2023 · Gritstone bio ( NASDAQ: GRTS) uses its vaccine technology to promote an immune response against a patients cancer or to prevent or treat infectious disease. In late September, 2023, GRTS announced ... Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product ...
Second Quarter 2023 Financial Results. Cash, cash equivalents, marketable securities and restricted cash were $122.3 million as of June 30, 2023, compared to $185.2 million as of December 31, 2022 ...
Mar 8, 2022 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone bio, Inc. Common Stock (GRTS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.The latest price target for Gritstone Bio ( NASDAQ: GRTS) was reported by Piper Sandler on Thursday, September 28, 2023. The analyst firm set a price target for 7.00 expecting GRTS to rise to ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical ...EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Gritstone Bio Inc (NASDAQ: GRTS)’s stock price has soared by 17.69 in relation to previous closing price of 1.30. Nevertheless, the company has seen a gain of 11.68% in its stock price over the last five trading days. Zacks Investment Research reported 2023-10-16 that Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy ...About Gritstone Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious ...Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable ...GRTS Latest Real Time Trades. Select time range to see more trades: Last 100 Trades. NLS Time (ET) NLS Price. NLS Share Volume. 16:00:04. $ 2.64. 861.WebGritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.
Gritstone bio, Inc. (GRTS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 1.3100 -0.0100 (-0.76%) As of 03:13PM EST. Market open. 1d 5d 1m 6m YTD 1y 5y
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.
Stock analysis for Gritstone bio Inc (GRTS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...About Gritstone bio Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines.American International Group Inc. purchased a new stake in Gritstone bio, Inc. (NASDAQ:GRTS – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 42,245 shares of the company’s stock, valued at approximately $82,000. Other large investors have also recently added to or …EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced... -- 10,000 participant randomized Phase 2b study will evaluate Gritstone s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus ...EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...As published in their initiating research note from Evercore ISI on March 31, 2023, Gritstone Bio Inc [GRTS] has been an Outperform. Analyzing GRTS Stock Performance. On Wednesday, Gritstone Bio Inc [NASDAQ: GRTS] plunged -7.65% to $1.69. The stock’s lowest price that day was $1.66, but it reached a high of $1.82 in the …Gritstone bio ( NASDAQ: GRTS) uses its vaccine technology to promote an immune response against a patients cancer or to prevent or treat infectious disease. In late September, 2023, GRTS announced ...(NASDAQ: GRTS) Gritstone Bio's forecast annual revenue growth rate of 76.39% is forecast to beat the US Biotechnology industry's average forecast revenue growth ...Verizon, Walgreens, and 4 Other Stocks. The S&P 500's Best Payouts: 7%+ Dividend Yields. Get the latest GRTS (GRTS) real-time quote, historical performance, charts, and other financial...
EMERYVILLE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...6 ธ.ค. 2564 ... (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI ...Based on analysts offering 12 month price targets for GRTS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Instagram:https://instagram. health insurance companies delawarebaron partners fundgreek mansiongeneral motors stock forecast EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced... -- 10,000 participant randomized Phase 2b study will evaluate Gritstone s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus ... Dec 13, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. surgetrader trustpilotstock talk Financials. GRTS has a market cap of $169mn and a cash balance of $153mn. Research and development expenses were $30.5 million for the three months ended March 31, 2023 while general and ...About Gritstone bio Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and ... pre ipo investment platform Jan 9, 2022 · Insiders seem to have made the most of their holdings by selling US$221k worth of Gritstone bio, Inc. (NASDAQ:GRTS) stock at an average sell price of US$22.10 during the past year. The company's ... The Oct. 25 announcement pushed Gritstone's stock from $2.23 per share that morning to $2.43 at the next day's opening, a 9% increase. Five Gritstone PIPE investors received 6.6 million shares for ...